Global News Aggregator
Anti-obesity drugmakers Novo Nordisk and Eli Lilly have a huge lead on their competition, but given the vast and valuable market, rivals are still eager to join the race. Bank…
Health care may be a real challenger to tech this year, a business that can actually grow faster than most of tech and has the possibility of a comeback from…
Check out the companies making headlines in midday trading. Regeneron Pharmaceuticals — Shares of the biotech firm edged more than 1% higher, adding to Wednesday’s gains. The moves follow a…
For many struggling with obesity, new medications have been “a gift,” as Oprah Winfrey recently described it in declaring she was “done with the shaming.” Investors in drug manufacturers Novo…
Investors are contemplating where and when the next big obesity drug deal will occur. At the moment, Novo Nordisk and Eli Lilly have the growing obesity drug market all to…
One of the downsides of taking new anti-obesity medications is that patients tend to lose lean muscle mass along with body fat. What this means for patients over the long…
Regeneron Pharmaceuticals (REGN) rose Monday after the Food and Drug Administration approved a higher-dose formulation of Eylea, the company’s macular degeneration treatment. If you like this story, sign up for…
The impact of new weight loss treatments is being felt well beyond the health-care industry . Analysts used the ritual of quarterly earnings calls to probe companies on whether their…
A view of the Regeneron Pharmaceuticals headquarters in Tarrytown, New York. Lev Radin | LightRocket | Getty Images Shares of Regeneron fell nearly 9% Tuesday after the U.S. Food and…
Jack Dorsey, chief executive officer of Square Inc., second right, tours the floor of the New York Stock Exchange (NYSE) in New York, U.S., on Thursday, Nov. 19, 2015. Yana…